| 9.52 -0.14 (-1.45%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.6 | 1-year : | 13.56 |
| Resists | First : | 9.93 | Second : | 11.6 |
| Pivot price | 8.89  |
|||
| Supports | First : | 8.74 | Second : | 8.01 |
| MAs | MA(5) : | 9.36 |
MA(20) : | 9.02 |
| MA(100) : | 9.56 |
MA(250) : | 13.89 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.9 |
D(3) : | 74.8 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 23.29 | Low : | 6.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATEC ] has closed below upper band by 23.4%. Bollinger Bands are 8.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.76 - 9.81 | 9.81 - 9.84 |
| Low: | 9.34 - 9.41 | 9.41 - 9.45 |
| Close: | 9.43 - 9.52 | 9.52 - 9.59 |
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
Sat, 01 Aug 2026
Enterprise value to revenue forward of Alphatec Holdings, Inc. – NASDAQ:ATEC - TradingView
Sat, 01 Aug 2026
Alphatec Holdings, Inc. Revenue Breakdown – NASDAQ:ATEC - TradingView
Wed, 29 Jul 2026
ATEC|Alphatec Holdings Inc|Price:9.730|Chg%:+0.080 - TradingKey
Wed, 29 Jul 2026
ATEC|Alphatec Holdings Inc|Price:9.670|Chg%:+0.020 - TradingKey
Mon, 27 Jul 2026
ATEC Announces Participation in Upcoming Investor Conferences - Business Wire
Thu, 23 Jul 2026
Alphatec (ATEC) Wells Fargo 20th Annual Healthcare Conference 2025 Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 154 (M) |
| Shares Float | 122 (M) |
| Held by Insiders | 20.4 (%) |
| Held by Institutions | 77.8 (%) |
| Shares Short | 13,750 (K) |
| Shares Short P.Month | 12,360 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.04 |
| Profit Margin | -16 % |
| Operating Margin | -11.5 % |
| Return on Assets (ttm) | -3.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 3.59 |
| Sales Per Share | 5.11 |
| EBITDA (p.s.) | 0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 52 (M) |
| Levered Free Cash Flow | 55 (M) |
| PE Ratio | -11.47 |
| PEG Ratio | 0.4 |
| Price to Book value | -238.01 |
| Price to Sales | 1.86 |
| Price to Cash Flow | 28.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|